Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy  44% ORR and 94% DCR in ccRCC patients previously treated with

KURA

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology reports promising results in late-stage kidney cancer trial

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Kura Oncology announced promising preliminary results from the FIT-001 trial showing 44% objective response rate and 94% disease control rate for darlifarnib in cabozantinib-pretreated ccRCC patients. This has significant implications for KURA, highlighting potential for overcoming drug resistance and increasing investment interest.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Kura&#039;s darlifarnib shows 44% ORR in ccRCC patients after cabozantinib.</li><li>94% disease control rate indicates potential to overcome treatment resistance.</li><li>75% of patients experienced tumor shrinkage; durable effects lasting 56 weeks.</li><li>Data presented at 2026 IKCS may catalyze further investment interest.</li><li>Kura to host a virtual event to discuss results.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Cabozantinib (N/A): KURA&#039;s results suggest complementarity to cabozantinib in ccRCC patients.</li></ul>
 </section>

 <section data-block="category">
 <h3>Research Analysis</h3>
 This falls under &#039;Research Analysis&#039; as it highlights clinical trial results that could alter treatment protocols and affect stock performance through potential revenue generation from new therapies.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Trial results may influence KURA&#039;s share price positively due to high efficacy metrics.</li><li>Upcoming investor event could drive additional interest and volatility in the stock.</li><li>Positive responses from analysts on the efficacy data may stimulate upward price momentum.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>FIT-001 trial involved 16 patients with ccRCC post-cabozantinib.</li><li>Objective response rate (ORR) reported at 44%.</li><li>Disease control rate (DCR) was 94%.</li><li>Tumor shrinkage seen in 75% of patients.</li><li>Treatment durations ranged from 8 to 56 weeks.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider KURA as a potential buy given strong clinical data and market interest.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off Manageable safety and tolerability profile in all RCC patients across multiple dose levels Virtual investor event today, April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO and PARIS, April 17, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KURA">KURA</a>), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib in the ongoing FIT-001 clinical trial (<a href="https://www.globenewswire.com/Tracker?data=zujc6Xs7Y8lnceVqc72aqyaiWErKcL6W1j4T7pPl8Zgjs8utYJgxaMkspLWKxqAq-voLDtI7sMS_k18OaA2iY_4h5rt32C5mZ7CWu8Hvw1WkvqDVZ1Hydw3zrtWckh7z" rel="nofollow" target="_blank">NCT06026410)</a> of darlifarnib (KO-2806) in combination with cabozantinib. Results were presented at the 2026 International Kidney Cancer Symposium (IKCS): Europe in Paris, France. The analysis specifically evaluated patients with ccRCC who had previously received cabozantinib, a population that typically derives limited benefit from subsequent therapy. In this setting, the combination of darlifarnib and cabozantinib demonstrated robust antitumor activity along with a manageable safety profile as demonstrated in all RCC patients across multiple dose levels, including full dose cabozantinib. These findings are consistent with clinical and preclinical data presented at the <a href="https://www.globenewswire.com/Tracker?data=EWbuKc-eZLXizHZuJDR6yMKd7QRos8hFKiNik-NP2O5xcSw0MZPAr5e6hMUaB8FD02HBSy2K9d_177PkRbfuR7mmJUtbvh-QgKo7ShvxquwQXBD6tCbFtn0a4qv-qECZ9ud3kfrTa1l_jgOAoNeVy5O18dwyDhxlZD2C-36vDLUdI2DnvRx4ZTYE4tRWHLbOG_ti-ktNkwTBGR1oyCILWww_Ev2zo3cMMbnX3FgvFqHdNdO4BWIYnhbhLjZ62VUK" rel="nofollow" target="_blank">2025 European Society for Medical Oncology (ESMO)</a> and in <a href="https://www.globenewswire.com/Tracker?data=cV9EEBO2-19Lpbnt4JSSRNJziAzN4vUzJb0MoSfUxhmfBps6F6CXco6Sz6tE9aIcGs2Z_f1iF1smNjHaQD1-7FKEi-UeX-7Qp7qKZzt-DFXV9QIR8dnCzZbzh3NzT2_-WEUVW4X2E_gq2gsC0SUYUqEoFSDrFMpSWU-nYg7YH9WqJE2Uh6rhenbMNIlL36QAU-6zrKjPdzWxdTz3f03ju6bzToMg4qDpctUdfykTuQg=" rel="nofollow" target="_blank">earlier data disclosures</a> supporting the potential of darlifarnib to enhance the activity of VEGFR-targeted therapies and to address mechanisms of resistance. Clinical Activity in Cabozantinib-Pretreated Patients (N=16): <ul type="disc"><li>Objective response rate (ORR) was 44%, with a disease control rate (DCR) of 94% across all doses tested in this population </li><li>Tumor shrinkage observed in 75% of patients, with reductions ranging from 32% to 47% among responders </li><li>Antitumor activity observed in a heavily pre-treated, cabozantinib-exposed population, including patients whose best response to prior cabozantinib was stable disease </li><li>Responses observed in patients previously treated with cabozantinib in the immediate prior line as well as those who had received other TKIs in addition to cabozantinib </li><li>Treatment durations ranged from 8 to 56 weeks, with six patients remaining on therapy at the time of data cutoff </li></ul> These findings are notable given that patients who progress on cabozantinib are generally considered unlikely to respond to subsequent cabozantinib therapy. "Patients with advanced ccRCC whose disease progresses on cabozantinib have limited treatment options," said Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. "The tumor shrinkage and high disease control rate observed with darlifarnib in combination with cabozantinib suggest this approach may offer meaningful clinical benefit in a refractory setting or in patients with disease progression after therapy." The FIT-001 study is evaluating darlifarnib in patients with RCC at once-daily doses of 3 mg, 5 mg or 8 mg alternating 7 days on and off in combination with cabozantinib at once-daily doses of 60 mg or 40 mg. All patients must have received prior immunotherapy. The study has advanced into Phase 1b dose expansion to assess an optimal biologically active dose for the combination. "These data highlight the potential of darlifarnib to overcome resistance to prior cabozantinib and enhance the activity of VEGF TKIs in patients with advanced RCC," said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. "We are highly encouraged by these results and are committed to advancing this combination to evaluate further its potential to deliver meaningful benefit for RCC patients." 2026 IKCS: Europe Presentation The presentation from 2026 IKCS: Europe is available on Kura's website at <a href="https://www.globenewswire.com/Tracker?data=6zNNGR5bwr25GqXtexAhRVouvkYGxAfg_r5rQ5Wp_w0pIu7cRJoXypyjQ98s2BLI42Am8oTSayxRxw8iEkCG8SsaW7oEPH4KROyBHZ1MbCA=" rel="nofollow" target="_blank">www.kuraoncology.com</a> under the Posters and Presentations tab in the <a href="https://www.globenewswire.com/Tracker?data=668_4UQ1C1e7ZMi6d4A28jLMeCnh2DHqd26P2C6HWUL7-JY7Mr5G1OW1VvpgNQZ53WByV2OAYvvHhdHkufGichNbN5zgBQQPMvveTohvIIvs0s3HWafUMh_dCv1iyGwrYoTpcijDqoVNZeSpddIZzJYQPU3BwAJbk04ADPenOt13urwP2EqBkohe8KkVBvzyFiPK2ldO-QMIHwVFkxCjyA==" rel="nofollow" target="_blank">Farnesyl Transferase Inhibition</a> section. Virtual Investor Event Kura will host a webcast and conference call today, April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST featuring management and Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology and Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. The live webcast and replay will be available on the Company's website at <a href="https://www.globenewswire.com/Tracker?data=6zNNGR5bwr25GqXtexAhRVouvkYGxAfg_r5rQ5Wp_w2abU-HY2gOTJqIkl4BNMgxlofB9kZyDdT0ZlNHJhqI3tvFOtkWBWZQwc72mww2V_I=" rel="nofollow" target="_blank">www.kuraoncology.com</a> under the Investors tab in the <a href="https://www.globenewswire.com/Tracker?data=g4k_5hOBILla_8eMcf9_3MVv4nwl48HlqIZHs1DMniP67XtqSOD1hnH7pPqCqzojfaHphmmD1MQ03gnceAW07Pqwid-FrmMmT0_Qab5Xbg498-PopOG3-tAbxPtCTXmRlrBcpHpmivyUkdG9Yot-3g==" rel="nofollow" target="_blank">Events and Presentations</a> section. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI&#x2122; (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at <a href="https://www.globenewswire.com/Tracker?data=2EKANpd4ONMR9h10hdJWdPoO5otTDt0oG4BNdDZ7oHs2_TCg06QxgbI9_2Hqyi_MZ4pHDRRIkdENWNTWbOsZVlzPSCzDUF3wv-4uUf7Vmak=" rel="nofollow" target="_blank">https://kuraoncology.com/</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=rer_N7Brn3-9G-CCQ23fvqQmWKyLAY3aNNoLE9CFc1OyUM_vII88BhKlYxXWYVTB7JO7NDryW88PfSZddRlb4g==" rel="nofollow" target="_blank">X</a> and <a href="https://www.globenewswire.com/Tracker?data=HBcXiRYy96A7IdzV5cHvQ9ky5Hu_V9UvH_kaeJWj-YD5YFe-Y6Uy-rIcFxbJyq26YEsYKCY_83uReRermRQMBkTvtYJB3OJ0eqoqt4CNWS_inO7d_X-gWpw6993QCITY" rel="nofollow" target="_blank">LinkedIn</a>. Forward-Looking Statements  This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of darlifarnib to enhance the activity of cabozantinib and other VEGFR-targeted therapies and to address mechanisms of resistance, and the potential of darlifarnib in combination with cabozantinib to offer meaningful clinical benefit to patients with RCC. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.  Conflict of Interest Disclosure Dr. Ayanambakkam&#39;s disclosures include consulting or advisory roles with Regeneron, Pfizer Oncology, Astellas Pharma, Bristol Myer Squibb – WINN CDA, Pharmacosmos Therapeutics, Natera Oncology, Foundation Medicine,National Cancer Institute, Native American Center of Cancer Health Excellence, AVEO, Johnson &amp; Johnson, Kura Oncology. Kura Contact Investors and Media: Greg Mann 858-987-4046 <a href="https://www.globenewswire.com/Tracker?data=ucpsxWIV4uHqJ_52zadN1vH_bTv56-LK8VTz5hyQOL8ay0Er18SqLGgWV3odn9MJ-My-scbqnsNFtDK_Je7ILxNwlRwnyLHLFnaPoliiozg=" rel="nofollow" target="_blank">gmann@kuraoncology.com</a> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5MTc1NiM3NTQwNjk1IzIwMTcxOTU="></img> <img alt="" src="https://ml.globenewswire.com/media/MTMzZGM3YjQtYjljNC00OWFjLTkzZWItOTlkNWUyZWQzYWQyLTEwMjg3NjgtMjAyNi0wNC0xNy1lbg==/tiny/Kura-Oncology-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ebf510d7-3727-4cc8-894f-6ce2d82b941a"><img src="https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a>

Kura Oncology announced promising preliminary results from the FIT-001 trial showing 44% objective response rate and 94% disease control rate for darlifarnib in cabozantinib-pretreated ccRCC patients. This has significant implications for KURA, highlighting potential for overcoming drug resistance and increasing investment interest.

kura-oncology-reports-darlifarnib-plus-cabozantinib-demonstrates-robust-activity-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Research Analysis

Related News